Home › Alzheimer's Disease › Michigan
Alzheimer's Disease clinical trials in Michigan
15 studies for Alzheimer's Disease are looking for participants at sites in Michigan.
Cities in Michigan
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- Local Institution - 1620, Troy
RecruitingPhase 3
Ages 55 to 90 · All sexes · Updated Sep 28, 2026 · NCT06937229A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
- Quest Research Institute, Farmington Hills
RecruitingPhase 4
Ages 50 and older · All sexes · Updated Sep 25, 2026 · NCT07633470A Study of LY3439539 in Participants With Alzheimer's Disease
- QUEST Research Institute, Farmington Hills
RecruitingPhase 1
Ages 50 to 85 · All sexes · Updated Sep 24, 2026 · NCT07598370A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
- QUEST Research Institute, Farmington Hills
RecruitingPhase 2
Ages 55 to 85 · All sexes · Updated Sep 22, 2026 · NCT07589595A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Neurobehavioral Medicine Group (NBMG), Bloomfield Township
RecruitingPhase 3
Ages 55 to 90 · All sexes · Updated Sep 22, 2026 · NCT06585787Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- Quest Research Institute, Farmington Hills
RecruitingPhase 3
Ages 50 to 90 · All sexes · Updated Sep 21, 2026 · NCT07177352A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
- QUEST Research Institute, Farmington Hills
RecruitingPhase 3
Ages 60 to 85 · All sexes · Updated Sep 17, 2026 · NCT06976203A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
- NeuroBehavioral Medicine Group, Bloomfield Hills
- Oakland Medical Research, Troy
RecruitingPhase 3
Ages 55 to 90 · All sexes · Updated Sep 16, 2026 · NCT07011732Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders
- Michigan Medicine, Ann Arbor
Recruiting
Ages 70 and older · All sexes · Updated Sep 8, 2026 · NCT05929703Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
- Local Institution - 0088, Sterling Heights
RecruitingPhase 2
Ages 55 to 90 · All sexes · Updated Sep 1, 2026 · NCT06808984Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Henry Ford Health System, Detroit
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Aug 4, 2026 · NCT06563895Michigan Healthy Mom (MI-MOM) Pregnancy Improvement Web Application Trial
- Shiawasee Health Department, Corunna
- McLaren Flint OB-GYN, Flint
- Munson Gaylord OB-GYN, Gaylord
- and 5 more
Recruiting
Ages 18 and older · Women · Updated Jul 24, 2026 · NCT07213284A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
- Revival Research Institute, LLC, Southfield
RecruitingPhase 3
Ages 55 and older · All sexes · Updated Jul 7, 2026 · NCT07602582A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
- QUEST Research Institute, Farmington Hills
RecruitingPhase 1Healthy volunteers welcome
Ages 45 to 85 · All sexes · Updated Jun 4, 2026 · NCT06657768Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
- Quest Research Institute, Farmington Hills
RecruitingObservational studyHealthy volunteers welcome
Ages 60 to 90 · All sexes · Updated Apr 15, 2026 · NCT06584357From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.